Holen Sie sich die Stockscreener-App
21.26
0.76%
0.16
Handel nachbörslich:
21.26
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD) - Stock Titan
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices - Fierce Pharma
Biopharmas look to China, elsewhere for partnerships, R&D - MSN
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle By Investing.com - Investing.com Canada
Trading the Move, Not the Narrative: (ACAD) Edition - Stock Traders Daily
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts - Sahm
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle - Investing.com UK
ACAD Technical Analysis | Trend, Signals & Chart Patterns | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACAD: Remlifanserin advances in ADP, NUPLAZID expands reach, and DAYBUE STIX boosts patient persistence - TradingView
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth - Barchart.com
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story - simplywall.st
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia Pharmaceuticals (ACAD) CEO Highlights Global R&D Partners - GuruFocus
Biopharmas look to China, elsewhere for partnerships, R&D (ACAD:NASDAQ) - Seeking Alpha
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady By Investing.com - Investing.com Australia
Earnings call transcript: ACADIA Q1 2026 misses forecasts, stock steady - Investing.com
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
ACAD Q1 earnings & revenues miss estimates despite Y/Y sales growth - MSN
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms - sharewise.com
UBS Group AG Buys 104,546 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - 富途牛牛
BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $34 - Moomoo
Earnings Miss: ACADIA Pharmaceuticals Inc. Missed EPS By 58% And Analysts Are Revising Their Forecasts - Yahoo Finance
(ACAD) Volatility Zones as Tactical Triggers - Stock Traders Daily
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback - Sahm
Acadia reaffirms 2026 total revenue guidance of $1.22B-$1.28B as remlifanserin Phase II ADP readout nears - MSN
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns - Sahm
What ACADIA Pharmaceuticals (ACAD)'s Earnings Miss, EU Setback and R&D Transition Means For Shareholders - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Lowered to $32 - GuruFocus
ACADIA Pharmaceuticals stock (US0042251084): Focus on CNS drug pipeline and commercial execution - AD HOC NEWS
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2026 Earnings Call Transcript - Insider Monkey
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):